Neu­rode­gen­er­a­tion up­start De­nali out­lines $100M IPO for its grow­ing clin­i­cal work

Can a team of neu­rode­gen­er­a­tion spe­cial­ists and at least one ear­ly-stage drug as­set out of Roche’s world-fa­mous Genen­tech group suc­ceed where so many have failed be­fore it?

I don’t know, but De­nali Ther­a­peu­tics is in the process of try­ing to raise rough­ly $100 mil­lion through an IPO to find out — which is just a frac­tion of the $350 mil­lion it gath­ered from some A list in­vestors in its ven­ture megarounds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.